A key effect of human papillomavirus (HPV) infection is to disrupt the normal cell cycle in order to subvert the cellular DNA replication machinery. Morphologically, condylomata induced by high and low risk HPV types cannot be distinguished and many studies have shown that the pattern of viral gene expression is similar in condylomata caused by both high risk and low risk HPV types. Detailed morphological study of cell cycle protein expression has not previously been performed on condylomata infected with low risk HPV types. The findings presented suggest that the mechanisms employed by low risk HPV6 or HPV11 to subvert cellular functions in condylomata acuminata are similar to those employed by high risk HPVs, with the exception of cyclin D1 and p53 protein over-expression. The differences in p53 expression and cyclin D1 expression seen between high and low risk HPV infection, reflect the known differences between high and low risk types and are in agreement with the known differences between high risk and low risk E6 and E7 proteins. PHK transduction studies demonstrated HPV E6 and E7 induce changes in cell cycle protein expression and that there are differences in cell cycle abrogation between HPV6 and HPV16. Disruption of the p53-MDM2 interaction can lead to activation of the p53 pathway. HPV infected lesions almost always contain wild-type p53. The binding of HPV E6 to p53, and its subsequent targeting for degradation, prevents activation of the p53 pathway in HPV infected cells. Cells over expressing HPV genes were treated with Nutlin-3, a MDM2-small molecule antagonist. The findings presented suggest treatment with Nutlin-3 induces cell cycle arrest in cells expressing HPV16 E7 and HPV6 E6 and HPV6 E7. This suggests a potential role for Nutlin-3 in the treatment of HPV infected cells.

Le VPH-16 de même que certains VPH, dont le VPH-18, causent le cancer du col utérin. Son intégration dans le génome humain pourrait être un marqueur de progression de l’infection. Les charges virales totale et intégrée sont présentement mesurées en quantifiant par PCR en temps réel les gènes E6 (RT-E6) et E2 (RT-E2-1) du VPH-16. Nous avons évalué l’impact du polymorphisme du gène E2 sur la quantification de l’ADN du VPH-16 dans des spécimens cliniques. Dans un premier temps, le gène E2 de 135 isolats de VPH-16 (123 appartenaient au clade Européen et 12 à des clades non- Européens) fut séquencé. Ensuite, un test de PCR en temps réel ciblant les séquences conservées dans E2 (RT-E2-2) fut développé et optimisé. Cent trente-neuf spécimens (lavages cervicaux et vaginaux) provenant de 74 participantes (58 séropositives pour le VIH, 16 séronégatives pour le VIH) ont été étudiés avec les trois tests E2 (RT-E2-2), E6 (RT-E6) et E2 (RT-E2-1). Les ratios de la quantité d’ADN de VPH-16 mesuré avec RT-E2-2 et RT-E2-1 dans les isolats Européens (médiane, 1.02; intervalle, 0.64-1.80) et Africains 1 (médiane, 0.80; intervalle, 0.53-1.09) sont similaires (P=0.08). Par contre, les ratios mesurés avec les isolats Africains 2 (médiane, 3.23; intervalle, 1.92-3.49) ou Asiatique- Américains (médiane, 3.78; intervalle, 1.47-37) sont nettement supérieurs à ceux obtenus avec les isolats Européens (P<0.02 pour chaque comparaison). Les distributions des quantités de E2 contenues dans les 139 échantillons mesurées avec RT-E2-2 (médiane, 6150) et RT-E2-1 (médiane, 8960) étaient statistiquement différentes (P<0.0001). Nous avons observé que les charges virales totale (odds ratio (OR) OR, 2.16 95% intervalle de confiance (IC) 1.11-4.19), et épisomale du VPH-16 (OR, 2.14 95% IC 1.09-4.19), mais pas la présence de formes intégrées (OR, 3.72 95% IC 1.03-13.4), sont associées aux néoplasies intraepitheliales cervicales de haut grade (CIN-2,3), et ce, en contrôlant pour des facteurs confondants tels que l’âge, le taux de CD4 sanguin, l’infection au VIH, et le polymorphisme de VPH-16. La proportion des échantillons ayant un ratio E6/E2 > 2 pour les femmes sans lésion intraépithéliale (7 de 35) est similaire à celle des femmes avec CIN-2,3 (5 de 11, p=0.24) ou avec CIN- 1 (4 de14, P=0.65). Le polymorphisme du gène E2 est un facteur qui influence la quantification des charges intégrées de VPH-16. / Episomal and integrated HPV-16 loads are currently estimated by quantitation with real-time PCR of HPV-16 E6 (RT-E6) and E2 (RT-E2-1) DNA. We assessed the impact of HPV-16 E2 polymorphism on quantitation of integrated HPV-16 DNA in clinical specimens. First, HPV-16 E2 was sequenced from 135 isolates (123 from European and 12 from non-European lineages). A novel assay targeting conserved HPV-16 E2 sequences (RT-E2-2) was optimized and applied with RT-E6 and RTE2- 1 on 139 HPV-16-positive cervicovaginal lavages collected from 74 women (58 HIV-seropositive, 16 HIV-seronegative). Ratios of HPV-16 DNA copies measured with RT-E2-2 and RT-E2-1 with European (median, 1.02; range, 0.64-1.80) and African 1 (median, 0.80; range, 0.53-1.09) isolates were similar (P=0.08). Ratios obtained with African 2 (median, 3.23; range, 1.92-3.49) or Asian-American (median, 3.78; range, 1.47-37) isolates were greater than those with European isolates (P<0.02 for each comparison). Distributions of HPV-16 E2 copies measured in 139 samples with RT-E2-2 (median, 6150) and RT-E2-1 (median, 8960) were different (P<0.0001). HPV-16 total (odds ratio (OR) OR, 2.16 95% confidence interval (CI) 1.11-4.19), episomal (OR, 2.14 95% CI 1.09-4.19) but not integrated (OR, 3.72 95% CI 1.03-13.4) load, were associated with high-grade cervical intraepithelial neoplasia (CIN-2,3) after controlling for age, CD4 count and HIV, and HPV-16 polymorphism. The proportion of samples with an E6/E2 ratio >2 in women without SIL (7 of 35) was similar to that of women with CIN-2,3 (5 of 11, P=0.24) or CIN-1 (4 of 14, P=0.65). E2 polymorphism was a factor that influenced measures of HPV-16 integrated load.

Problématique : Bien que le tabac et l’alcool soient les facteurs causaux principaux des cancers épidermoïdes de l’oropharynx, le virus du papillome humain (VPH) serait responsable de l’augmentation récente de l’incidence de ces cancers, particulièrement chez les patients jeunes et/ou non-fumeurs. La prévalence du VPH à haut risque, essentiellement de type 16, est passée de 20% à plus de 60% au cours des vingt dernières années. Certaines études indiquent que les cancers VPH-positifs ont un meilleur pronostic que les VPH- négatifs, mais des données prospectives à cet égard sont rares dans la littérature, surtout pour les études de phase III avec stratification basée sur les risques. Hypothèses et objectifs : Il est présumé que la présence du VPH est un facteur de bon pronostic. L’étude vise à documenter la prévalence du VPH dans les cancers de l’oropharynx, et à établir son impact sur le pronostic, chez des patients traités avec un schéma thérapeutique incluant la chimio-radiothérapie. Méthodologie : Les tumeurs proviennent de cas traités au CHUM pour des cancers épidermoïdes de la sphère ORL à un stade localement avancé (III, IVA et IVB). Elles sont conservées dans une banque tumorale, et les données cliniques sur l’efficacité du traitement et les effets secondaires, recueillies prospectivement. La présence du VPH est établie par biologie moléculaire déterminant la présence du génome VPH et son génotype. Résultats: 255 spécimens ont été soumis au test de génotypage Linear Array HPV. Après amplification par PCR, de l’ADN viral a été détecté dans 175 (68.6%) échantillons tumoraux ; le VPH de type 16 était impliqué dans 133 cas (52.25 %). Conclusion: Une proportion grandissante de cancers ORL est liée au VPH. Notre étude confirme que la présence du VPH est fortement associée à une amélioration du pronostic chez les patients atteints de cancers ORL traités par chimio-radiothérapie, et devrait être un facteur de stratification dans les essais cliniques comprenant des cas de cancers ORL. / Background: HPV is recognised as a good prognostic factor in head and neck (H&N) cancer. However, most of the data is derived from randomised trials with different treatment options or small heterogeneous cohorts. This trial aims to determine the prevalence and prognostic impact of HPV on overall survival (OS), disease-free survival (DFS), local regional control (LRC) and treatment toxicity, in patients with locally advanced SCCHN treated with concomitant platinum-based chemoradiation therapy (CRT) and followed prospectively. Methods: Prospective data on efficacy and toxicity was available for 560 patients treated with CRT. Of these, 270 fixed and paraffin embedded specimens were collected. DNA was extracted from specimens and HPV detection was performed as previously described (Coutlée, J Clin Microbiol, 2006). Analysis was performed using Kaplan-Meier survival curves, Fisher's test for categorical data and log-rank statistics for failure times. Results: Median follow-up was 4.7 years. DNA extraction was successful in 255 cases. HPV prevalence was 68.6%, and 53.3% for HPV-16 specifically. For HPV+ and HPV- respectively, median LRC were 8.9 and 2.2 years (log-rank p = 0.0002), median DFS were 8.9 and 2.1 years (log-rank p=0.0014) and median OS were 8.9 and 3.1 years (log-rank p=0.0002). Survival was statistically significantly different based on HPV genotype, stage, treatment period and chemotherapy regimen. COX adjusted analysis for T, N, age, and treatment remained significant (HR 0.45, p=0.004). Subgroup analysis for genotype, TNM, primary site and chemotherapy regimen will be presented at the meeting. Conclusions: An increasing proportion of oropharyngeal cancer is linked to HPV. This large study with confirms that HPV status is strongly associated with improved prognosis among H&N cancer patients receiving CRT, and should be a stratification factor for clinical trials including H&N cases. Toxicity of CRT is not modified for the HPV population.

Le virus du papillome humain (VPH) est l’agent étiologique du cancer du col utérin, ainsi que d’autre néoplasies anogénitales et des voies aérodigestives supérieures. La réplication de son génome d’ADN double brin est assurée par les protéines virales E1 et E2, de concert avec la machinerie cellulaire de réplication. E1 assure le déroulement de l’ADN en aval de la fourche de réplication, grâce à son activité hélicase, et orchestre la duplication du génome viral. Nos travaux antérieurs ont démontré que le domaine N-terminal de E1 contient un motif de liaison à la protéine cellulaire p80/UAF1 qui est hautement conservé chez tous les VPH anogénitaux. L’intégrité de ce motif est essentielle au maintien de l’épisome viral. Les travaux présentés dans cette thèse ont d’abord déterminé que le motif de liaison à UAF1 n’est pas requis pour l’assemblage du pré-réplisome viral, mais important pour la réplication subséquente de l’ADN du VPH. Nous avons constaté qu’en présence de E1 et E2, UAF1 est relocalisé dans des foyers nucléaires typiques de sites de réplication du virus et qu’en outre, UAF1 s’associe physiquement à l’origine de réplication du VPH. Nous avons aussi déterminé que l’inhibition du recrutement de UAF1 par la surexpression d’un peptide dérivé de E1 (N40) contenant le motif de liaison à UAF1 réduit la réplication de l’ADN viral. Cette observation soutient le modèle selon lequel UAF1 est relocalisé par E1 au réplisome pour promouvoir la réplication de l’ADN viral. UAF1 est une protéine à domaine WD40 n’encodant aucune activité enzymatique et présumée exploiter des interactions protéine-protéine pour accomplir sa fonction. Nous avons donc investigué les protéines associées à UAF1 dans des cellules du col utérin et avons détecté des interactions avec les enzymes de déubiquitination USP1, USP12 et USP46, ainsi qu’avec la phosphatase PHLPP1. Nous avons établi que E1 forme un complexe ternaire avec UAF1 et n’importe laquelle des USP associés : USP1, USP12 ou USP46. Ces USP sont relocalisés au noyau par E1 et s’associent à l’ADN viral. De plus, l’activité enzymatique des USP est essentielle à la réplication optimale du génome viral. Au contraire, PHLPP1 ne forme pas de complexe avec E1, puisque leurs interactions respectives avec UAF1 sont mutuellement exclusives. PHLPP1 contient un peptide de liaison à UAF1 homologue à celui de E1. Ce peptide dérivé de PHLPP1 (P1) interagit avec le complexe UAF1-USP et, similairement au peptide N40, antagonise l’interaction E1-UAF1. Incidemment, la surexpression du peptide P1 inhibe la réplication de l’ADN viral. La génération de protéines chimériques entre P1 et des variants de E1 (E1Δ) défectifs pour l’interaction avec UAF1 restaure la capacité de E1Δ à interagir avec UAF1 et USP46, ainsi qu’à relocaliser UAF1 dans les foyers nucléaires contenant E1 et E2. Ce recrutement artificiel de UAF1 et des USP promeut la réplication de l’ADN viral, un phénotype dépendant de l’activité déubiquitinase du complexe. Globalement, nos travaux suggèrent que la protéine E1 du VPH interagit avec UAF1 afin de recruter au réplisome un complexe de déubiquitination dont l’activité est importante pour la réplication de l’ADN viral. / Human papillomaviruses (HPVs) are the etiological agents of cervical cancers, as well as multiple other anogenital and oropharyngeal neoplesias. The viral proteins E1 and E2, in concert with the host DNA replication machinery, mediate the replication of the double-stranded DNA genome of HPV. E1 exploits its helicase activity to unwind DNA ahead of the replication fork and orchestrates synthesis of the viral genome. Our previous work demonstrated that E1 contains in its N-terminus a binding motif for the host protein p80/UAF1, a domain that is highly conserved amongst anogenital HPVs. The integrity of this region was essential for the maintenance of the viral episome. The research presented here first demonstrated that the UAF1-binding motif is not required for the assembly of the E1-E2-Origin pre-replisome, but important for the following viral DNA replication. We have determined that UAF1 is relocalized, in presence of E1 and E2, in nuclear foci reminiscent of viral DNA synthesis sites. UAF1 also physically interacted, through E1-binding, with the viral origin of replication. Moreover, we have shown that inhibition of E1-UAF1 interaction through the overexpression of an E1-derived and UAF1-binding peptide, N40, interferes with HPV DNA replication. This is in agreement with the model according to which E1 recruits UAF1 to the replisome to promote viral DNA replication. UAF1 is a WD40-containing protein with no enzymatic activity and presumed to function through interactions with other cellular factors. We have investigated the UAF1 interaction network in cervical cells and discovered that UAF1 associates with the deubiquitinating enzymes USP1, USP12 and USP46, as well as with the phosphatase PHLPP1. E1 was found to assemble as a ternary complex with UAF1 and any of the associated USPs: USP1, USP12 or USP46. These USPs were also relocalized by E1 to the nucleus and they associated with the viral origin in presence of E2. Moreover, their enzymatic function was essential for optimal viral genome replication. In contrast, PHLPP1 did not associate with E1, and the interactions of the latter proteins with UAF1 were shown to be mutually exclusive. PHLPP1 contains a UAF1-binding motif homologous to the one encoded within E1. This PHLPP1-derived peptide, P1, interacts with the UAF1-USP complex and, similarly to N40, competes with E1-UAF1 interaction. Accordingly, P1 overexpression leads to inhibition of HPV DNA replication. The fusion of the peptide P1 to an E1 protein (E1Δ) defective for UAF1-binding restored its capacity to interact with UAF1 and USP46, as well as to relocalize UAF1 into E1-E2-containing nuclear foci. This artificial recruitment of UAF1 and of the associated USPs increased viral DNA replication, a process that involved the enzymatic activity of the USPs. Collectively, our work suggests that HPV E1 interacts with UAF1 in order to recruit to the replisome a deubiquitinating complex whose activity is required for optimal viral DNA replication.

O câncer de colo do útero é a segunda principal causa de morte em mulheres por câncer, sendo causado principalmente pela infecção persistente por HPV. A principal forma atual de prevenção desse câncer é a realização de exames citológicos periódicos e a vacinação profilática disponibilizada recentemente pelo Ministério da Saúde. Entretanto, tais ações visam a prevenção da infecção por HPV ou a detecção de lesões, pois não há um tratamento específico contra infecções e lesões já estabelecidas. Dentre as proteínas expressas por HPV, L2 está presente no capsídeo viral e é bem conservada entre diversos tipos de HPV, enquanto E6 é uma proteína oncogênica capaz de induzir a transformação maligna das células. Este estudo visa o desenvolvimento de uma vacina profilática e terapêutica capaz de proteger contra a infecção por diversos tipos virais, assim como combater as células já modificadas por qualquer tipo de HPV. Assim, foi construído um vetor vacinal contendo peptídeos selecionados das proteínas L2 e E6 de HPV16 testadas em modelo murino, para avaliar sua eficiência como vacina de DNA ministrada antes ou após desafio com células tumorais. Os ensaios em modelo animal demonstraram que a vacina foi capaz de induzir a produção de anticorpos específicos anti-L2 e anti-E6, assim como induzir a produção de citocinas TNF e impedir o desenvolvimento tumoral de células HPV-positivas. Portanto, foi possível concluir que o vetor construído foi capaz de induzir uma resposta imune humoral e celular em camundongos, capaz de prevenir contra o HPV, assim como tratar os cânceres a ele associados. / Cervical cancer is the second most frequent cause of death in women due to cancer, mainly caused by persistent HPV infection. The primary prevention method of this cancer is through periodic cytological exams and prophylactic vaccination which has been recently made available by the Ministry of Health. However, such actions aim towards prevention of HPV infection or the detection of lesions, since there is no specific treatment against pre-existing infections and injuries. Among the proteins expressed by HPV, L2 is present in the viral capsid and is well conserved among several types of HPV, whereas E6 is an oncogenic protein, capable of inducing malignant mutations in cells. This study aims towards the development of a prophylactic and therapeutic vaccine, capable of protecting against infections caused by several viral types, as well as combating cells which have already been modified by any type of HPV. Thus, a vaccine vector, containing peptides selected from HPV16s L2 and E6 proteins, tested in the murine model, was constructed in order to evaluate its efficiency as a DNA vaccine, to be administered either before or after challenging with tumour cells. The animal model assays demonstrated that the vaccine was able to induce the production of anti-L2 and anti-E6 specific antibodies, as well as TNF cytokines, and to prevent tumour development in HPV-positive cells. Therefore, it was possible to conclude that the designed vector was indeed able to induce humoral and cellular immune responses in mice, capable of preventing against HPV, as well as of treating cancers associated with it.

INTRODUÇÃO: A epidermodisplasia verruciforme (EV) é uma rara genodermatose, associada ao beta-papilomavírus humano (Beta-HPV) e alto risco de desenvolvimento de câncer de pele. As claudinas são proteínas transmembranas expressas nos diversos epitélios e podem se alterar na carcinogênese. Para melhor compreensão do papel do Beta-HPV na carcinogênese cutânea, realizou-se um estudo da expressão das claudinas nos pacientes com e sem EV. MÉTODOS: Um painel de anticorpos anti-claudina -1, -2, -3, -4, -5, -7 e -11 foi empregado para analisar a expressão dessa proteína em 108 amostras de pele normal, 39 verrugas planas e 174 carcinomas espinocelulares cutâneo (CEC), obtidas de 33 pacientes com epidermodisplasia verruciforme (EV) e 112 indivíduos saudáveis (não EV- NEV). As amostras de CEC foram organizadas em 4 microarranjos teciduais. A análise estatística foi realizada por regressão logística para verificar as alterações do perfil de claudinas na carcinogênese e sua relação com idade, sexo e fotoexposição crônica nos doentes com EV e o grupo NEV. RESULTADOS: A expressão focal da claudina-1 apresentou associação com o CEC (p < 0,001) e a expressão não difusa (focal ou negativa) da claudina-2 esteve associado a verruga plana (p < 0,001), nos grupos EV e NEV. A expressão focal da claudina-3 apresentou associação com o CEC (p < 0,001), bem como a imunomarcação nuclear da claudina-3 (p < 0,001), em ambos os grupos. Adicionalmente, a chance da expressão nuclear da claudina-3 foi 53% menor nas áreas não fotoexpostas. A claudina-5 apresentou maiores porcentagens de expressão focal na pele normal, de expressão difusa no CEC e na verruga plana EV, e de expressão negativa na verruga plana NEV. O grupo EV apresentou menor chance de expressão focal e negativa (p < 0,001). Além disso, a negatividade da claudina-5 esteve associada a verruga plana (p < 0,001) e menor média de idade (p < 0,001). As claudinas -4, -7 e -11 apresentaram expressão difusa em quase todas as amostras estudadas, nos grupos EV e NEV. CONCLUSÕES: Verificou-se aumento progressivo da claudina-5 na carcinogênse cutânea e esse processo apresentou relação com a EV. Redução da expressão das claudinas -1 e -3 foi observada nos carcinomas cutâneos, e da claudina-2 nas verrugas planas, no entanto, não puderam ser relacionadas à infecção pelo beta-HPV. Idade e fotoexposição crônica foram fatores que influenciaram a expressão da claudina-5 e a expressão nuclear da claudina-3, respectivamente / BACKGROUND: Epidermodysplasia verruciformis (EV) is a rare genodermatosis, related to human beta-papillomavirus (Beta-HPV), with high risk for developing skin cancer. Claudins are transmembrane proteins expressed in epithelia and may be altered on carcinogenesis. Toward better understanding the role of Beta-HPV in cutaneous carcinogenesis, claudin expression study was performed in lesions of patients with and without EV. METHODS: A panel of anti-claudin antibodies was assembled to analyze claudins -1, -2, -3, -4, -5, -7 and -11 expression, by immunohistochemistry technique, in samples of 108 normal skin, 39 flat warts and 174 cutaneous squamous cell carcinomas (SCC), obtained from 33 patients with EV and 112 individuals without EV (not-EV - NEV). The SCC samples were organized in tissue microarrays. Statistical analysis was performed by logistic regression, aiming to verify changes in claudin profile in carcinogenesis and its relationship with age, sex and chronic sun exposure area, in patients with and without EV. RESULTS: Claudin-1 focal expression was associated with SCC (p < 0.001) and claudin-2 focal or negative expression with flat wart (p < 0.001), in EV and NEV groups. Claudin-3 focal expression was related with SCC (p < 0.001), as well as the nuclear immunostaining of claudin-3 (p < 0.001), in both groups. Additionally, chance of claudin-3 nuclear expression was 53% lower in not sun exposed areas. For claudin-5, focal expression was more common in normal skin, diffuse expression in SCC annd EV flat wart, and negative expression in NEV flat wart. The EV group showed lower chance of focal and negative expression (p < 0.001). In addition, the negativity of claudin-5 expression was associated with flat wart (p < 0.001) and lower mean age (p < 0.001). Claudins -4, -7 and -11 showed, in both groups, diffuse expression in almost all studied samples. CONCLUSIONS: Claudin-5 increasing expression was observed in cutaneous carcinogenesis and this process showed association with EV. Claudin-1 and -3 down expression were observed in cutaneous carcinomas, and claudin-2 in flat warts, however, they could not be related with Beta-HPV infection. Age and chronic sun exposure area were factors that influenced claudin-5 and claudin-3 nuclear expression, respectively

The latest model of tertiary structure of capsid protein of potato virus X (PVX CP) was used as a template to design new insertion sites suitable for the preparation of PVX-based antigen presentation system. Based on this model, seven insertion sites (A-G) located in putative surface loops were tested. As an antigen inserted into these sites was used 17 amino acids long epitope derived from human papillomavirus type 16 E7 oncoprotein (E7 epitope) fused with either 6xHis tag or StrepII tag in both possible orientations (6xHis-E7 and E7-6xHis, StrepII-E7 and E7-StrepII). Prior to plant expression, modified PVX CPs were expressed in Escherichia coli MC1061. The results showed that only PVX CP carrying StrepII-E7 or E7-StrepII in the insertion site A formed virus particles. The results from transient expression experiments with modified PVX CPs in Nicotiana benthamiana showed that only the insertion site A (located between 24th and 25th amino acid in the PVX CP) could tolerate all tested inserts. Importantly, viral particles were detected only in the presence of StrepII tag and their stability was affected by the insert orientation (StrepII-E7 vs. E7-StrepII) as only the viral particles presenting E7-StrepII could be purified. Besides the preparation of PVX-based antigen presentation system, an...

O desenvolvimento do câncer cervical está associado à infecção por alguns tipos de Papilomavírus Humano (HPV). Entre os mecanismos de carcinogênese associados ao HPV incluem-se alterações em moléculas que modulam a manutenção de componentes da matriz extracelular (MEC), como as metaloproteinases de matriz (MMP) e alguns de seus reguladores. A proteína RECK (reversion inducing cysteine rich protein with kazal motifs) apresenta função essencial na remodelação tecidual e na angiogênese fisiológica ou tumoral, através da regulação pós-transcricional da atividade de MMP-2, MMP-9 e MMP-14 (MT1-MMP). Resultados publicados previamente por nosso grupo apontam para a correlação entre a expressão da oncoproteína E7 de HPV16, a alta expressão e atividade de MMP-9 e a baixa expressão de seus reguladores, TIMP-2 e RECK. A expressão de RECK também é baixa em lesões do colo uterino de alto grau e em amostras de câncer cervical, quando comparadas a amostras de pacientes com cervicite. O presente estudo visa determinar o papel de RECK no processo de tumorigênese mediado por HPV. Para isto, estabelecemos linhagens derivadas de tumor de colo de útero (SiHa, SW756 e C33A) que superexpressam RECK a partir de transdução com lentivírus. Os efeitos da superexpressão de RECK sobre o potencial tumorigênico de SiHa, SW756 e C33A foram avaliados em modelos de estudo in vivo e in vitro. De maneira geral, a superexpressão de RECK foi associada com a capacidade reduzida de invasão em câmara de Matrigel® e de formação de colônia independente de ancoragem. Ainda, camundongos nude inoculados s.c. com células tumorais superexpressando RECK apresentaram atraso no estabelecimento e crescimento tumoral e sobrevida global estendida quando comparados aos controles. Ambos tumores derivados de SiHa RECK e SW756 RECK apresentaram redução na frequência de células tumorais e endoteliais, ao passo que mostrarm aumento no infiltrado inflamatório. Esta observação foi acompanhada de redução na população de neutrófilos e potenciais células mieloderivadas supressoras em tumores de ambas as linhagens. Em tempo, analisamos séries de dados de expressão de CIN e carcinomas cervicais do banco de dados GEO e verificamos que a hipermetilação do gene RECK e a inibição da expressão de mRNA de RECK são eventos precoces no desenvolvimento do câncer de colo de útero. Avaliamos que a baixa expressão de RECK foi associada a progressão de lesões CIN3+ e ao aumento de metástases em linfonodo pélvico em pacientes com câncer de colo de útero. Ademais, notamos que o tratamento com quimio radioterapia levou ao aumento dos níveis de mRNA de RECK em um outro grupo de pacientes com câncer de colo de útero. Concluímos que a superexpressão de RECK (i) reduz o potencial tumorigênico de linhagens celulares derivadas de colo de útero independente do status de infecção por HPV e que (ii) o seu efeito sobre as populações intratumorais se mostrou específico para as linhagens infectadas por HPV. Estes resultados apontam para uma possível interação entre as alterações no microambiente tumoral associadas ao HPV e a função de RECK. Finalmente, a regulação negativa da expressão de RECK é um evento precoce na história natural do câncer cervical. / Persistent infection with high-risk Human Papillomavirus (HPV) types is the main etiologic factor for the development of cervical cancer. The HPV carcinogenic mechanisms include alterations in extracellular matrix (ECM) components, as matrix metalloproteinases (MMP) and its regulators. The Reversion-inducing Cysteine-rich protein with Kazal motifs (RECK) plays a central role on tissue remodeling, tumor angiogenesis and exert inhibitory effects on the transcription, synthesis, activation and activity of MMP-2, MMP-9 e MMP-14 (MT1-MMP). As previously published by our group, it has been observed a correlation between the HPV16 E7 oncoprotein expression, the up-regulation of MMP-9 and the down-regulation of its inhibitors, RECK and tissue inhibitor of metalloproteinases 2 (TIMP-2). Also, RECK expression was downregulated in cervical intraepithelial neoplasias grades 2 and 3 (CIN2/3) and invasive carcinoma samples levels when compared with clinical samples of pacients diagnosed with cervicitis. The present study aims to determine the role of RECK in HPV mediated tumorigenesis. In order to do so, we generated cervical tumors derived cell lines (SiHa, SW756 e C33A) superexpressing RECK by lentiviral transduction followed by FACS. We assessed the effects of RECK superexpression in the tumorigenic potential of SiHa, SW756 e C33A using both in vitro and in vivo protocols. Overall, RECK superexpression is associated with reduced chamber invasion and reduced anchorage independent colony formation. Moreover, nude mice injected s.c. with RECK superexpressing tumor cells presented (i) delayed tumor establishment and (ii) increased overall survival, when compared with controls. Both SiHa and SW756 superexpressing RECK presented decreased frequency of tumor and endothelial cells, whilst showed increase in inflammatory infiltrate population. This observation was followed by a decrease in potential myeloid derived suppressor cell and neutrophil populations in both SiHa RECK and SW756 RECK tumors. Additionally, we observed hipermethylation and premature and consistent downregulation of RECK mRNA expression in CIN and cervical cancer expression datasets from GEO database. We observed that reduced RECK expression was associated with CIN3+ progression and increased pelvic lymph node metastasis in cervical cancer patients. Furthermore, we found that chemo radiotherapy treatment led to increased levels of mRNA in another set of cervical cancer patients. We conclude that RECK superexpression reduces the tumorigenic potential of cervical cancer derived cell lines regardless of HPV infection status. However, we found that the effect of RECK over the intratumoral cells populations is specific to HPV infected tumor cell lines. These results points to a possible interaction between HPV associated tumor microenvironment alterations and RECK. Finally, RECK downregulation is an early event in the natural history of cervical cancer.

Estudo prospectivo para identificar a presença do papilomavírus humano em gestantes adolescentes por meio da captura híbrida II e correlacionar com colpocitologia oncótica convencional, em base líquida e colposcopia. O grupo constituído por 60 gestantes entre 12 a 18 anos e idade gestacional media de 23 semanas. A captura híbrida II foi positiva em 51,7%. A colpocitocologia oncótica convencional : normal em 90% e anormal em 10%. Os achados citológicos anormais: lesão intraepitelial escamosa de baixo grau em 8,3% e carcinoma invasor em 1,7%. A colpocitologia em base líquida: normal em 90% e anormal em 10%. Os achados citológicos anormais: lesão intraepitelial escamosa de baixo grau em 8,3% e lesão intraepitelial escamosa de alto grau em 1,7%. Os achados colposcópicos normais foram o epitélio escamoso normal em 20%, epitélio glandular em 18,3% e a zona de transformação normal em 40%. A zona de transformação anormal presente em 21,7% / Study delineated to identify human papillomavirus by hybrid capture II in pregnant teenagers and to correlate with conventional, liquid-based Pap test and colposcopic findings. The study group was constituted by 60 pregnant women aged between 12 and 18 years old; mean gestational age was 23 weeks. They were submitted to anamnese, Pap smear, hybrid capture technique and colposcopy. Hybrid capture II of human papillomavirus was positive in 51,7% of the cases. Conventional Pap test was normal in 90% and abnormal in 10% of the cases. Abnormal results: low-grade squamous intraepithelial lesion in 8,3% and Invasor carcinoma in 1,7%. Based-liquid Pap test was normal in 90% and abnormal in 10% of the cases. Abnormal results: 8,3% of low-grade squamous intraepithelial lesion and 1,7% of high-grade squamous intraepithelial lesion. Normal results: 20% of normal squamous epithelium, 18,3%of columnar epithelium and 40% of normal transformation zone. Abnormal transformation zone was seen in 21,7% of the cases

Infecção pelo HPV é o principal fator de risco para câncer cervical. Os tumores apresentam microambiente complexo, células tumorais e inflamatórias integram sinais modulando a atividade de vias de sinalização. Caracterizamos o estado de ativação de três vias de sinalização importantes para a progressão tumoral. Com o aumento do grau da lesão, observamos: aumento da expressão de NF&#954;B e Akt fosforiladas no microambiente tumoral; redução de NF&#954;B fosforilada e aumento de STAT3 e Akt fosforiladas em leucócitos circulantes. Em modelos experimentais, a via de NF&#954;B também encontra-se inibida, principalmente em células apresentadoras de antígenos. Para testar se a modulação de vias de sinalização poderiam alterar as respostas a tumores, tratamos linfócitos B de pacientes com agonista de CD40, ativador de NF&#954;B, e observamos aumento do potencial de apresentação antigênica. Nossos resultados mostram o panorama do estado de ativação de importantes vias de sinalização para a progressão tumoral e trazem a possibilidade de uma ferramenta imunomoduladora. / Cervical cancers have HPV infection as a main factor. HPV tumors recruit leucocytes and change their phenotype as an evasion mechanism. We tried to understand how the tumor influences the immune cells behavior, analyzing signaling pathways important to tumor progression in cervical biopsy and PBMC from patients with high-grade lesions and cancer. We find an increase in NF&#954;B activation in immune cells from tumor microenvironment, but a decrease in PBMC. We could not find any difference in STAT3 signaling pathway in the tumor microenvironment, however, there was an activation increase in PBMC. Both tumor microenvironment immune cells and PBMC had an increase in Akt signaling pathway. To identify a possible strategy to reverse the tumor influence, we stimulated B lymphocytes from patients with sCD40L, achieving an increase in the numbers of CD80+CD86+ cells. Our results demonstrate a tumor effect over the immune cells, with an important systemic effect. However, the approach used to stimulate B lymphocytes from patients present us with a possible immunotherapy.